Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jul 5, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help people with major depressive disorder (MDD) reduce their tendency to ruminate, or repeatedly think about negative feelings and experiences. Researchers are using advanced brain imaging technology, specifically a type of MRI called 7-Tesla, to provide real-time feedback to patients. By focusing on certain areas of the brain that are linked to rumination, the goal is to help participants change their brain activity in a way that might lessen their depressive thoughts and improve their mood.

To participate in this study, individuals must be between the ages of 18 and 65 and either currently experiencing major depression or have no past psychiatric diagnoses. Participants should be able to understand English well enough to follow instructions and consent to the study. It's important to note that individuals with certain mental health issues, active substance use disorders, or serious health conditions, as well as those who are pregnant or currently hospitalized for psychiatric issues, will not be eligible for this trial. If you join the study, you can expect to engage in brain training sessions that aim to help reduce negative thinking patterns, which could be beneficial for your mental health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female aged 18-65 years who either meet DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI) for major depressive disorder (MDD) with a current major depressive episode OR does not meet for any current or past psychiatric diagnoses
• • Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process
• Exclusion Criteria:
• • Any current or history of schizophrenia or other psychotic disorder, neurodevelopmental disorder, or neurocognitive disorder for patients, active substance use disorder within the past 6 months
• • Unstable medical illness, concomitant use of any medication with central nervous system activity within 1 week of MRI scan
• • Pregnancy
• • Patients who are currently hospitalized in the inpatient psychiatric units at Mount Sinai Hospital or involuntarily admitted/court-ordered
• • Subjects judged to be at serious and imminent suicidal or homicidal risk by the study-affiliated psychiatrist or another MD, and contradictions to MRI